Extremely high and specific activity of DNA enzymes in cells with a Philadelphia chromosome

Chemistry and Biology

Volumn 6, Issue 4, 1999, Pages 237-250

  Warashina, Masaki ^a,b   Kuwabara, Tomoko ^a,b   Nakamatsu, Yuka ^a,b   Taira, Kazunari ^a,b  

^a NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY AIST   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Antisense oligonucleotide; Chronic myelogenous leukemia (CML); DNA enzyme; Hammerhead ribozyme; Phosphorothioate

Indexed keywords

ANTISENSE DNA; ANTISENSE OLIGONUCLEOTIDE; CHIMERIC GENE; CHROMOSOME TRANSLOCATION; CHRONIC MYELOID LEUKEMIA; ENZYME ACTIVITY; ENZYME MODIFICATION; ENZYME SPECIFICITY; GENE FUSION; GENETIC TRANSFECTION; MAMMAL CELL; MESSENGER RNA; METHYLATION; PHOSPHOROTHIOIC ACID; RIBOZYME;

EID: 0033117651     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1074-5521(99)80039-8     Document Type: Article

References (72)

1. Nowell, P.C., & Hungerford, D.A. (1960). A minute chromosome in human chronic granulocytic leukemia. Science 132, 1497-1499.
2. Rowley, J.D. (1973). A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and giemsa staining. Nature 243, 290-293.
3. Bartram, C.R., et al., & Groffen, J. (1983). Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukemia. Nature 306, 277-280.
4. Heisterkamp, N., et al., & Grosveld, G. (1983). Localization of the c-ab1 oncogene adjacent to a translocation break point in chronic myelocytic leukemia. Nature 306, 239-242
5. Groffen, J., et al., & Grosveld, G. (1984). Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 36, 93-99.
6. Shtivelman, E., Lifshitz, B., Gale, R.P. & Canaani, E. (1985). Fused transcript of abl and bcr genes in chronic myelogenous leukemia. Nature 315, 550-553.
7. Shtivelman, E., Lifschitz, B., Gale, R.P., Roe, B.A. & Canaani, E. (1986). Alternative splicing of RNAs transcribed from the human abl gene and from the BCR-ABL fused gene. Cell 47, 277-284.
8. Konopka, J.B., Watanabe, S.M. & Witte, O.N. (1984). An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity. Cell 37, 1035-1042.
9. Shore, S.K., Nabissa, P.M. & Reddy, E.P. (1993). Ribozyme-mediated cleavage of the BCR-ABL oncogene transcript: In vitro cleavage of RNA and in vivo loss of P210 protein-kinase activity. Oncogene 8, 3183-3188.
10. Snyder, D. S., et al., & Forman, S. J. (1993). Ribozyme-mediated inhibition of BCR-ABL gene expression in a Philadelphia chromosome-positive cell line. Blood 82, 600-605.
11. Lange, W., Cantin, E. M., Finke, J. & Dolken, G. (1993). In vitro and in vivo effects of synthetic ribozymes targeted against BCR/ABL mRNA. Leukemia 7, 1786-1794.
12. Wright, L., Wilson, S.B., Milliken, S., Biggs, J. & Kearney, P. (1993). Ribozyme-mediated cleavage of the bcrlabl transcript expressed in chronic myeloid leukemia. Exp. Hematol. 21, 1714-1718.
13. Lange, W., Daskalakis, M., Finke, J. & Dolken, G. (1994). Comparison of different ribozymes for efficient and specific cleavage of BCR/ABL related mRNAs. FEBS Lett. 338, 175-178.
14. Kearney, P., Wright, L.A., Milliken, S. & Biggs, J.C. (1995). Improved specificity of ribozyme-mediated cleavage of BCR-ABL mRNA. Exp. Hematol. 23, 986-989.
15. Leopold, L.H., Shore, S.K., Newkirk, T.A., Reddy, R.M.V. & Reddy, P. (1995). Multi-unit ribozyme-mediated cleavage of BCR-ABL mRNA in myeloid leukemias. Blood 8, 2162-2170.
16. Kronenwett, R., Haas, R. & Sczakiel, G. (1996). Kinetic selectivity of complementary nucleic acids: Bcr-abl-directed antisense RNA and ribozymes. J. Mol. Biol. 259, 632-644.
17. Pachuk, C.J., Yoon, K., Moelling, K. & Coney, L.R. (1994). Selective cleavage of BCR-ABL chimeric RNAs by a ribozyme targeted to non-contiguous sequence. Nucleic Acids Res. 22, 301-307.
18. James, H., Mills, K. & Gibson, I. (1996). Investigating and improving the specificity of ribozymes directed against the BCR-ABL translocation. Leukemia 10, 1054-1064.
19. Hertel, K. J., Herschlag, D., & Uhlenbeck, O.C. (1996). Specificity of hammerhead ribozyme cleavage. EMBO J. 15, 3751-3757.
20. Birikh, K. R., Heaton, P. A., & Eckstein, F. (1997). The hammerhead ribozyme-structure, function and application. Eur. J. Biochem. 245, 1-16.
21. O'Brien, S. G., et al., & Goldman, J. M. (1994). Antisense BCR-ABL oligomers cause non-specific inhibition of chronic myeloid leukemia cell lines. Leukemia 8, 2156-2162.
22. Maekawa, T., et al., & Abe, T. (1995). Sequence specificity on the growth suppression and induction of apoptosis of chronic myeloid leukemia cells by BCR-ABL anti-sense oligonucleoside phosphorothioates. Int. J. Cancer 62, 63-69.
23. Manon, F.X., et al., & Reiffers, J. (1995). Inhibition of chronic myelogenous leukemia cells harboring a BCR-ABL B3A2 junction by antisense oligonucleotides targeted at the B2A2 junction. Exp. Hematol. 23, 1606-1611.
24. Smetsers, T.F., et al., & Mensink, E.J. (1995). Phosphorothioate BCR-ABL antisense oligonucleotides induce cell death, but fail to reduce cellular BCR-ABL protein levels. Leukemia 9, 118-130.
25. Vaerman, J.L., et al., & Martiat, P. (1995). BCR-ABL antisense oligodeoxyribonucleotides suppress the growth of leukemic and normal hematopoietic cells by a sequence-specific but nonantisense mechanism. Blood 86, 3891-3896.
26. Smetsers, T.F., Linders, E.H., van de Locht, L.T., de Witte, T.M., & Mensink, E.J. (1997). An antisense BCR-ABL phosphodiester-tailed methylphosphonate oligonucleotide reduces the growth of chronic myeloid leukemia patient cells by a nonantisense mechanism. Br. J. Hematol. 96, 377-381.
27. Vaerman, J.L., et al., & Martiat, P. (1997). Antisense oligodeoxyribonucleotides suppress hematologic cell growth through stepwise release of deoxyribonucleotides. Blood 90, 331-339.
28. Kuwabara, T., Warashina, M., Tanabe, T., Tani, K., Asano, S. & Taira, K. (1997). Comparison of the specificities and catalytic activities of hammerhead ribozymes and DNA enzymes with respect to the cleavage of BCR-ABL chimeric L6 (b2a2) mRNA. Nucleic Acids Res. 25, 3074-3081.
29. Kuwabara, T., Warashina, M., Tanabe, T., Tani, K., Asano, S. & Taira, K. (1998). A novel allosterically frans-activated ribozyme, the maxizyme, with exceptional specificity in vitro and in vivo. Mol. Cell 2, 617-627.
30. Santoro, S.W. & Joyce, G.F. (1997). A general purpose RNA-cleaving DNA enzyme. Proc. Natl Acad. Sci. USA 94, 4262-4266.
31. Santoro, S.W. & Joyce, G.F. (1998). Mechanism and utility of an RNA-cleaving DNA enzyme. Biochemistry 37, 13330-13342.
32. Ota, N., Warashina, M., Hirano, K., Hatanaka, K. & Taira, K. (1998). Effects of helical structures formed by the binding arms of DNAzymes and their substrates on catalytic activity. Nucleic Acids Res. 26, 3385-3391.
33. Kazakov, S. & Altman, S. (1992). A trinucleotide can promote metal ion-dependent specific cleavage of RNA. Proc. Natl Acad. Sci. USA 89, 7939-7943.
34. Dahm, S.C., Derrick, W.B. & Uhlenbeck, O.C. (1993). Role of divalent metal ions in the hammerhead RNA cleavage reaction. Biochemistry 32, 13040-13045.
35. Piccirilli, J.A., Vyle, J.S., Caruthers, M.H. & Cech, T.R. (1993). Metal ion catalysis in the Tetrahymena ribozyme reaction. Nature 361, 85-88.
36. Yarus. M. (1993). How many catalytic rnas? Ions and the cheshire cat conjecture. FASEB J. 7, 31-39.
37. 2+ ions in ribozyme reaction. FASEB J. 7, 137-142.
38. Steitz, T.A. & Steitz, J.A. (1993). A general two-metal-ion mechanism for catalytic RNA. Proc. Natl. Acad. Sci. USA 90, 6498-6502.
39. Sawata, S., Komiyama, M. & Taira, K. (1995). Kinetic evidence based on solvent isotope effects for the nonexistence of a proton-transfer process in reactions catalyzed by a hammerhead ribozyme: Implication to the double-metal-ion mechanism of catalysis. J. Am. Chem. Soc. 117, 2357-2358.
40. Pontius, B.W., Lott, W.B. & von Hippel, P.H. (1997). Observations on catalysis by hammerhead ribozymes are consistent with two-divalent-metal-ion mechanism. Prac. Natl Acad. Sci. USA 94, 2290-2294.
41. Zhou, D.-M., Zhang, L.-H., & Taira, K. (1997). Explanation by the double-metal-ion mechanism of catalysis for the differential metal ion effects on the cleavage rates of 5′-oxy and 5′-thio substrates by a hammerhead ribozyme. Proc. Natl Acad. Sci. USA 94, 14343-14348.
42. Lott, W.B., Pontius, B.W. & von Hippel P.H. (1998). A two-metal ion mechanism operates in the hammerhead ribozyme-mediated cleavage of an RNA substrate. Proc. Natl Acad. Sci. USA 95, 542-547.
43. Zhou, D.-M. & Taira, K. (1998). The hydrolysis of RNA: From theoretical calculations to the hammerhead ribozyme-mediated cleavage of RNA. Chem. Rev. 98, 991-1026.
44. Warashina, M., Zhou, D.-M., Kuwabara, T. & Taira, K. (1998). Ribozymes structure and function. In Preblotic Chemistry, Molecular Fossils, Nucleosides, and RNA, Comprehensive Natural Products Chemistry, vol. 6, (Söil, D. & Nishimura, S., vol. eds.; Barton, D.H.R. & Nakanishi, K., eds.-in-chief), Elsevier Science, Oxford.
45. Shimayama, T., Nishikawa, F., Nishikawa, S. & Taira, K. (1993). Nuclease-resistant chimeric ribozymes containing deoxyribonucleotides and phosphorothioate linkages. Nucleic Acids Res. 21, 2605-2611.
46. Heidenreich, O., Benseler, F., Fahrenholz, A. & Eckstein, F. (1994). High activity and stability of hammerhead ribozymes containing 2′-modified pyrimidine nucleotides and phosphorothioates. J. Biol. Chem. 269, 2131-2138.
47. Jarvis, T.C., et al., & Stinchcomb, D.T. (1996). Optimizing the cell efficacy of synthetic ribozymes. Site selection and chemical modifications of ribozymes targeting the proto-oncogene c-myb. J. Biol. Chem. 271, 29107-29112.
48. Usman, N. & Stinchcomb, D. T. (1996). Design, synthesis, and function of therapeutic hammerhead ribozymes. In Catalytic RNA, Nucleic Acids and Molecular Biology, vol. 10, (Eckstein, F. & Lilley, D.M.J., eds) pp. 243-264, Springer-Verlag, Berlin.
49. Sproat, B. S. (1996). Synthetic catalytic oligonucleotides based on the hammerhead ribozyme. In Catalytic RNA, Nucleic Acids and Molecular Biology, vol. 10, (Eckstein, F. & Lilley, D.M.J., eds) pp. 243-264, Springer-Verlag, Berlin.
50. Heidenreich, O. & Eckstein, F. (1992). Hammerhead ribozyme-mediated cleavage of the long terminal repeat RNA of human immunodeficiency virus type 1. J. Biol. Chem. 267, 1904-1909.
51. Marschall, P., Thomson, J.B. & Eckstein, F. (1994). Inhibition of gene expression with ribozymes. Cell. Mol. Neurobiol. 14, 523-538.
52. Scarabino, D. & Tocchini-Valentini, G.P. (1996). Influence of substrate structure on cleavage by hammerhead ribozyme. FEBS Lett. 383, 185-190.
53. Erickson, R.P. & Izant, J. (eds) (1992). Gene Regulation: Biology of Antisense RNA and DNA. Raven Press, New York.
54. Murray, J.A.H. (ed.) (1992). Antisense RNA and DNA. Wiley-Liss, Inc., New York.
55. Pegoraro, L., Matera, L., Ritz, J., Levis, A., Palumbo, A. & Biagini, G. (1983). Establishment of a Ph1-positive human cell line (BV173). J. Natl Cancer Inst. 70, 447-453.
56. Val-heterodimeric maxizymes with high potential as gene inactivating agents: Simultaneous cleavage at two sites in HIV-1 tat mRNA in cultured cells. Proc. Natl Acad. Sci. USA 96, 1886-1891.
57. Koseki, S., et al., & Taira, K. (1999). Factors governing the activity in vivo of ribozymes transcribed by RNA polymerase III. J. Virol. 73, 1868-1877.
58. Seyhan, A.A., Amaral, J. & Burke, J.M. (1998). Intracellular RNA cleavage by the hairpin ribozyme. Nucleic Acids Res. 26, 3494-3504.
59. Chapman, R.S., Whetton, A.D. & Dive, C. (1994). The suppression of drug-induced apoptosis by activation of v-abl protein tyrosine kinase. Cancer Res. 54, 5131-5137.
60. Laneuville, P., Timm, M. & Hudson, A.T. (1994). Bcr/abl expression in 32D c13(G) cells inhibits apoptosis induced by protein tyrosine kinase inhibitors. Cancer Res. 54, 1360-1368.
61. Spooncer, E., Fairbairn, L., Cowling, G.J., Dexter, T.M., Whetton, A.D. & Owen-Lynch, P.J. (1994). Biological consequences of p160 v-abl protein tyrosine kinase activity in primitive, multipotent hematopoietic cell line. Leukemia 8, 620-626.
62. Bedi, A., Zehnbauer, B.A., Barber, J.P., Sharkis, S.J. & Jones, R.J. (1994). Inhibition of apoptosis by BCR-ABL in chronic myelogenous leukemia. Blood 83, 2038-2045.
63. Bedi, A., et al., & Jones, R.J. (1995). BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: A mechanism of resistance to multiple anticancer agent. Blood 86, 1148-1153.
64. McGahon, A., Bissonnette, R., Schmitt, M., Cotter, K.M., Green, D.R. & Cotter, T.G. (1994). BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood 83, 1179-1187.
65. McGahon, A.J., Nishioka, W.K., Martin, S.J., Mahboubi, A., Cotter, T.G. & Green, D.R. (1995). Regulation of the Fas apoptotic cell death pathway by abl. J. Biol. Chem. 270, 22625-22631.
66. Dubrez, L., Eymin, B., Sordet, O., Droin, N., Turhan, A.G. & Solary, E. (1998). BCR-ABL delays apoptosis upstream of procaspase-3 activation. Blood 7, 2415-2422.
67. Val-driven short ribozymes. Nat. Biotechnol. 16, 961-965.
68. Warashina, M., Takagi, Y., Sawata, S., Zhou, D.-M., Kuwabara, T. & Taira, K. (1997). Entropically driven enhancement of cleavage activity of a DNA-armed hammerhead ribozyme: Mechanism of action of hammerhead ribozyme. J. Org. Chem. 62, 9138-9147.
69. Uchiyama, H., Hirano, K., Kashiwasake-Jibu M. & Taira, K. (1996). Detection of undegraded oligonucleotides in vivo by fluorescence resonance energy transfer: Nuclease activities in living sea urchin eggs. J. Biol. Chem. 271, 380-384.
70. Ota, N., et al., & Taira, K. (1998) Determination of interactions between structured nucleic acids by fluorescence resonance energy transfer (FRET): Selection of target sites for functional nucleic acids. Nucleic Acids Res. 26, 735-743.
71. Koseki, S., Ohkawa, J., Yamamoto, R., Takebe, Y. & Taira, K. (1998). A simple assay system for examination of the inhibitory potential in vivo of decoy RNAs, ribozymes and other drugs by measuring the tat-mediated transcription of a fusion gene composed of the long terminal repeat of HIV-1 and a gene for luciferase. J. Control. Release 53, 159-173.
72. Reuther, J.Y., Reuther, G.W., Cortez, D., Pendergast, A.M. & Baldwin, Jr., A.S. (1998). A requirement for NF-κB activation in Bcr-Abl-mediated transformation. Genes Dev, 12, 968-981.